FDA approves first anti-C1s antibody, targeting innate immunity for rare anaemia

被引：0
|
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 04期
关键词：
D O I：
10.1038/d41573-022-00049-7
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：249 / 249
页数：1
相关论文
共 50 条
  • [31] Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study
    Wahrmann, M.
    Muehlbacher, J.
    Marinova, L.
    Regele, H.
    Huttary, N.
    Eskandary, F.
    Cohen, G.
    Fischer, G. F.
    Parry, G. C.
    Gilbert, J. C.
    Panicker, S.
    Boehmig, G. A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (09) : 2300 - 2311
  • [32] First bivalent fully antagonist anti-c-Met antibody targeting the c-Met receptor: II) in vivo activity
    Goetsch, Liliane
    Lepecquet, Anne-Marie
    Geronimi, Fabien
    Gonzalez, Alexandra
    Robert, Alain
    Chenu, Stephane
    Corbiere, Jean-Claude
    Bailly, Christian
    Corvaia, Nathalle
    CANCER RESEARCH, 2009, 69
  • [33] THE ANTI C1S COMPLEMENT ANTIBODY TNT009 INDUCES RAPID COMPLETE REMISSIONS OF ANAEMIA IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE
    Jaeger, U.
    Gilbert, J. C.
    Panicker, S.
    Parry, G. C.
    Fillitz, M.
    Schenk, T.
    Sillaber, C.
    Bartko, J.
    Jilma, B.
    HAEMATOLOGICA, 2016, 101 : 341 - 341
  • [34] First bivalent fully antagonist anti-c-Met antibody targeting the c-Met receptor: I) in vitro mechanism of action
    Corvaia, Nathalie
    Gonzalez, Alexandra
    Boute, Nicolas
    Beau-Larvor, Charlotte
    Fabre-Lafay, Stephanie
    Geronimi, Fabien
    Broussas, Matthieu
    Lepecquet, Anne-Marie
    Robert, Alain
    Wurch, Thierry
    Haeuw, Jean-Francois
    Bailly, Christian
    Goetsch, Liliane
    CANCER RESEARCH, 2009, 69
  • [35] Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial
    Li, Yingxin
    Young Na, Joo
    Zhu, Yunting
    Oh, Jaeseong
    Zhao, Amy
    Jang, In-Jin
    Tang, Lei
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (10) : 1063 - 1074
  • [36] CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models
    Lv, Zhuangwei
    Zhang, Ping
    Li, Dandan
    Qin, Mengting
    Nie, Longzhu
    Wang, Xiaoqian
    Ai, Li
    Feng, Zhaozu
    Odhiambo, Woodvine Otieno
    Ma, Yunfeng
    Ji, Yanhong
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [37] Targeting tumor-intrinsic S100A1 augments antitumour immunity and potentiates anti-PD-1 efficacy
    Guo, Yufeng
    Bai, Hua
    Wang, Jie
    CANCER RESEARCH, 2024, 84 (06)
  • [38] Targeting the intrinsic signaling of PD-L1 in human monocytes by a novel PD-L1 antibody to promote anti-tumor immunity.
    Hsu, Michelle A.
    Liu, Xin
    Barham, Whitney
    Hirdler, Jacob
    Mao, Zhiming
    Lucien, Fabrice
    Dong, Haidong
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [39] ANTIBODY TARGETING NKG2D LIGANDS MICA/B TO UNLEASH ANTI-TUMOR IMMUNITY OF NK AND ILC1 CELLS
    Liu, Sizhe
    Smith, Tyler
    Zhu, Lisha
    Dhar, Payal
    Wu, Jennifer
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1054 - A1054
  • [40] Antibody Fc-receptor FcεR1γ stabilizes cell surface receptors in group 3 innate lymphoid cells and promotes anti-infection immunity
    Huang, Chao
    Zhu, Wenting
    Li, Qing
    Lei, Yuchen
    Chen, Xi
    Liu, Shaorui
    Chen, Dianyu
    Zhong, Lijian
    Gao, Feng
    Fu, Shujie
    He, Danyang
    Li, Jinsong
    Xu, Heping
    NATURE COMMUNICATIONS, 2024, 15 (01)
12345